<SEC-DOCUMENT>0001513162-20-000131.txt : 20200708
<SEC-HEADER>0001513162-20-000131.hdr.sgml : 20200708
<ACCEPTANCE-DATETIME>20200629204111
ACCESSION NUMBER:		0001513162-20-000131
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200629
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200629
DATE AS OF CHANGE:		20200708

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	DENTAL EQUIPMENT & SUPPLIES [3843]
		IRS NUMBER:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		20999628

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9496452111

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<head><title>Form 8-K</title> </head> <body lang=EN-US> <div style=page:WordSection1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>UNITED STATES </strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>WASHINGTON, D.C.</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>FORM 8-K</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><strong>CURRENT REPORT</strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Pursuant to Section 13 or 15(d) of the</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Securities Exchange Act of 1934</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align=center>Date of Report (date of earliest event reported): <b>June 29, 2020</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>BIOMERICA, INC.</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Exact Name of Registrant as Specified in its Charter)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <div align=center> <table width=693 bordercolor=transparent style=WIDTH:693px cellpadding=0 cellspacing=0> <tr> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Delaware</p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>001-37863</font></p></td> <td width=43 style="WIDTH:32.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td style="BORDER-TOP:0px; BORDER-RIGHT:0px; BORDER-BOTTOM:black 1pt solid; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; BORDER-LEFT:0px; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt 1.5pt; TEXT-INDENT:-1.5pt' align=center>95-2645573</p></td></tr> <tr> <td width=118 style="WIDTH:118px; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN-LEFT:0in; MARGIN-RIGHT:0in' align=left>(State or Other Jurisdiction of Incorporation)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=83 style="WIDTH:62.25pt; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=left>(Commission File Number)</p></td> <td style="PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt"> <td width=113 style="WIDTH:113px; PADDING-BOTTOM:0.75pt; PADDING-TOP:0.75pt; PADDING-LEFT:0.75pt; PADDING-RIGHT:0.75pt" valign=top> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=left>(IRS Employer Identification Number)</p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>17571 Von Karman Ave.</p> <h1 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0in 0pt'>Irvine, California 92614</h1> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Address of Principal Executive Offices</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Zip Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><u>949-645-2111</u></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Registrant&#146;s Telephone Number,</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Including Area Code)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'><strong>Not applicable</strong></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>(Former Name or Former Address if Changed</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>Since Last Report)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style="MARGIN:0in 0in 0pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="MARGIN:12pt 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="MARGIN:0in 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>1</font></p> <p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt"><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="MARGIN:0in 0in 0pt"><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'><font face=Wingdings>o</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style="MARGIN:3pt 0in 0pt; LINE-HEIGHT:120%">Securities registered pursuant to Section 12(b) of the Act:</p> <div align=center> <table width=683 bordercolor=transparent style=BORDER-COLLAPSE:collapse cellpadding=0 cellspacing=0> <tr style=HEIGHT:14pt> <td width=235 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:176pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Title of each class</font></u></b></p></td> <td width=92 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Trading Symbol</font></u></b></p></td> <td width=356 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:267pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><b><u style=text-underline:black><font style="FONT-SIZE:9pt; COLOR:black">Name of each exchange on which registered</font></u></b></p></td></tr> <tr style=HEIGHT:14pt> <td width=235 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:176pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">Common Stock, par value $0.08</font></p></td> <td width=92 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:69pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">BMRA</font></p></td> <td width=356 style="BORDER-TOP:0px; HEIGHT:14pt; BORDER-RIGHT:0px; WIDTH:267pt; BORDER-BOTTOM:0px; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:3pt; BORDER-LEFT:0px; PADDING-RIGHT:3pt" valign=bottom> <p style="PAGE-BREAK-AFTER:avoid; TEXT-ALIGN:center; MARGIN:2pt 0in" align=center><font style="FONT-SIZE:9pt; COLOR:black">NASDAQ Capital Market</font></p></td></tr></table></div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font face=Wingdings><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&nbsp;&nbsp; Emerging growth company&nbsp;&nbsp; <font face=Wingdings>o</font></font></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font face=Wingdings><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp; </font>o</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>2</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p><font face=Wingdings> <p style="MARGIN:0in 0in 0pt"><b><font face="Times New Roman">Item 7.01 Regulation FD Disclosures</font></b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p><font face="Times New Roman"> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">On June 29, 2020, Biomerica, Inc. (&#147;Biomerica&#148;) issued a press release announcing that it has signed a definitive agreement with the University of Texas Health Science Center at Houston to join the clinical trial for Biomerica&#146;s new InFoods&#174; <font style=COLOR:#002c40>diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. </font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of, or otherwise regarded as filed under, the&nbsp;Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Exchange Act, except as shall be expressly set forth by specific reference in such filing.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'></font>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><b>Item 8.01&nbsp; Other Events</b></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">On June 25, 2020, Biomerica, Inc. signed a definitive agreement with the <a name=_Hlk44323751>University of Texas Health Science Center at Houston </a>to join the clinical trial for Biomerica&#146;s new InFoods&#174; <font style=COLOR:#002c40>diagnostic-guided therapy designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. </font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif; COLOR:black'><strong>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Financial Statements and Exhibits</strong></font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; PADDING-LEFT:0px; MARGIN:0in 0in 0pt 48px'>(d)&nbsp; Exhibits</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'><strong><font style=FONT-SIZE:10pt><u>Number</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description</u></font></strong></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:justify; MARGIN:0in 0in 0pt'>99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman",serif'>Press Release issued June 29, 2020.</font></p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>3</font></p> <div style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center> <hr> <DIV style="PAGE-BREAK-BEFORE: always"> </DIV> </div> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'>&nbsp;</p> <h2 style='FONT-SIZE:12pt; TEXT-DECORATION:underline; FONT-FAMILY:"Times New Roman","serif"; PAGE-BREAK-AFTER:avoid; FONT-WEIGHT:normal; TEXT-ALIGN:center; MARGIN:0in 0.3in 0pt 0in'>SIGNATURE</h2> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0.3in 0pt 0in'>&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:right; MARGIN:0in 0.3in 0pt 0in' align=right>&nbsp;</p> <table width=600 bordercolor=transparent style="WIDTH:6.25in; BORDER-COLLAPSE:collapse; MARGIN-LEFT:-0.75pt" cellpadding=0 cellspacing=0> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><a name=T13><font style="FONT-SIZE:11pt; COLOR:black">Dated:&nbsp; June 30, 2020</font></a></p></td> <td width=47% colspan=2 nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Biomerica, Inc.</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom /> </tr><tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">By:</font></p></td> <td width=47% nowrap style="BORDER-TOP:0px; HEIGHT:15pt; BORDER-RIGHT:0px; WIDTH:47%; BORDER-BOTTOM:windowtext 1pt solid; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; BORDER-LEFT:0px; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">/s/&nbsp;Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Zackary S. Irani</font></p></td></tr> <tr style=HEIGHT:15pt> <td width=50% nowrap style="HEIGHT:15pt; WIDTH:50%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=3% nowrap style="HEIGHT:15pt; WIDTH:3%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <td width=47% nowrap style="HEIGHT:15pt; WIDTH:47%; PADDING-BOTTOM:0in; PADDING-TOP:0in; PADDING-LEFT:0in; PADDING-RIGHT:0in" valign=bottom> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; MARGIN:0in 0in 0pt'><font style="FONT-SIZE:11pt; COLOR:black">Chief Executive Officer</font></p></td></tr></table> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center>&nbsp;</p> <p style='FONT-SIZE:12pt; FONT-FAMILY:"Times New Roman","serif"; TEXT-ALIGN:center; MARGIN:0in 0in 0pt' align=center><font style=FONT-SIZE:11pt>4</font></p></div></body><!-- EDGAR Validation Code: ED0B6053 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<head><title>Exhibit 99.1</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <p style="MARGIN-BOTTOM:16px; MARGIN-TOP:0px">&nbsp;</p> <p style="MARGIN-BOTTOM:0px; MARGIN-TOP:8px"><img src=logo.jpg><br></p> <p style="FONT-SIZE:17.5pt; MARGIN-BOTTOM:0px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:12px; COLOR:#002c40"><b>The </b><b>University of Texas Health Science Center at Houston</b><b> </b><b>joins </b><b>Biomerica<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s InFoods</b><b>&#174;</b><b> Irritable Bowel Syndrome (</b><b>"</b><b>IBS</b><b>"</b><b>)</b><b> </b><b>D</b><b>iagnostic</b><b>-</b><b>G</b><b>uided </b><b>T</b><b>herapy </b><b>(<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>DGT<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) </b><b>clinical </b><b>trial. &nbsp;</b></p> <p style="MARGIN-BOTTOM:8px; MARGIN-TOP:0px"><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Courier New'; WIDTH:96px; MARGIN-TOP:0px; FLOAT:left; TEXT-INDENT:72px">-</p> <p style="FONT-SIZE:14.5pt; MARGIN-BOTTOM:10px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:0px; COLOR:#002c40; PADDING-LEFT:96px; TEXT-INDENT:-2px"><b>InFoods</b><b>&#174;</b><b> </b><b>Diagnostic</b><b>-</b><b>Guided Therapy </b><b>is</b><b> </b><b>d</b><b>esigned</b><b> to i</b><b>dentif</b><b>y</b><b> patient</b><b>-</b><b>specific foods</b><font style="FONT-SIZE:8pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000"> </font><b>that</b><b>,</b><b> when removed</b><b> from the diet</b><b>, </b><b>may </b><b>alleviate an individual's IBS symptoms</b></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px; CLEAR:left"><br></p> <p style="FONT-SIZE:11pt; MARGIN-BOTTOM:-2px; FONT-FAMILY:'Courier New'; WIDTH:96px; MARGIN-TOP:0px; FLOAT:left; TEXT-INDENT:72px">-</p> <p style="FONT-SIZE:14.5pt; MARGIN-BOTTOM:10px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:0px; COLOR:#002c40; PADDING-LEFT:96px; TEXT-INDENT:-2px"><b>Approximately </b><b>45 million Americans suffer from IBS</b><font style=FONT-SIZE:9pt><b><sup>1</sup></b><b> </b></font></p> <p style="MARGIN-BOTTOM:9px; MARGIN-TOP:0px; CLEAR:left"><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px" align=justify>IRVINE, CA--(June 29, 2020) - Biomerica Inc. (NASDAQ: <font style=COLOR:#0071bb>BMRA</font>) today announced it has signed a definitive agreement with the University of Texas Health Science Center at Houston (<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>UTH<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) to join the clinical trial for Biomerica<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s<font style="FONT-SIZE:11pt; FONT-FAMILY:'Times New Roman'; COLOR:#000000"> new InFoods&#174; </font>diagnostic-guided therapy, designed to alleviate Irritable Bowel Syndrome (IBS) symptoms. The University of Texas Health Science Center at Houston is the fifth large medical center to be part of the InFoods&#174; clinical trial which includes: &nbsp;Mayo Clinic, Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, Houston Methodist and the University of Michigan as primary enrollment centers. UTH can now begin enrollment of patients in this trial.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px" align=justify>It is estimated that over 45 million Americans suffer from IBS and the symptoms are often triggered by consumption of specific foods (which are unique in each sufferer). &nbsp;The total cost (direct + indirect) of IBS has been estimated at $30 billion annually in the United States. IBS is a common condition that can substantially impair physical and mental well-being of a patient and a person<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s ability to function both at home and in the workplace.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px" align=justify>A clinical lab version of the InFoods&#174; IBS DGT product is being used in this clinical trial. However, the Company is also working to develop a point-of-care version of the InFoods&#174; IBS DGT product that would potentially allow physicians to perform the test in-office using a finger stick blood sample. The point of care version would allow physicians to be reimbursed for administering the test. &nbsp;A billable CPT code that can be used by both clinical labs and physicians' offices is already available for the InFoods&#174; IBS products. Market research conducted by a leading, independent, pharmaceutical, marketing research firm, determined that over 70% of physicians surveyed would utilize the InFoods&#174; DGT to treat their IBS patients without reimbursement and over 90% would utilize it with reimbursement. &nbsp;</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px" align=justify>Importantly, the InFoods&#174; DGT can be used without or in conjunction with current IBS pharmaceuticals to potentially improve patient outcomes. Since the InFoods&#174; product is a diagnostic-guided therapy and not a drug, it has no drug-type side effects. &nbsp;&nbsp;&nbsp;</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px" align=justify>The current endpoint clinical trial is expected to be completed in approximately 6 months. However, due to the novel coronavirus<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font> impact on the U.S.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s healthcare system, it may take longer. If all goes as expected, </p> <p style=MARGIN:0px align=justify><br><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="FONT-SIZE:10.5pt; FONT-FAMILY:Avenir,Times New Roman; PAGE-BREAK-BEFORE:always; COLOR:#002c40; MARGIN:0px" align=justify>Biomerica plans to commence the final pivotal trial several months thereafter, which is needed for submission to the FDA for final clearance. &nbsp;The endpoint trial stratifies enrollment by the three main IBS subclasses (IBS-Constipation, IBS-Diarrhea and IBS-Mixed). The clinical study design has already received a non-significant risk determination from the FDA.</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:6px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:6px; COLOR:#002c40" align=justify>Dr. Brooks D. Cash, Chief of Gastroenterology, Hepatology, and Nutrition at the University of Texas Health Science Center at the Texas Medical Center, stated, <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>We are excited about the potential impact this can make for IBS patients and excited to be part of the clinical trial group for InFoods&#174; IBS. The product is novel in that it is addressing a root cause of IBS with a non-pharmaceutical therapy, yet can be combined with current pharmaceutical therapies to improve outcomes.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:6px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:6px; COLOR:#002c40" align=justify>Zackary Irani, Chief Executive Officer of Biomerica, commented: <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>IBS remains a major burden for up to 45 million people in the United States who desperately seek some form of medical advancement providing relief. &nbsp;We believe our approach, supported by a Scientific Advisory Board comprised of the leading minds in the IBS medical community, is differentiated by focusing on one possible root cause of IBS compared to simply treating symptoms.<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> &nbsp;</p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:6px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:6px; COLOR:#002c40"><b>About Biomerica (NASDAQ: </b><font style=COLOR:#0071bb><b>BMRA</b></font><font style=COLOR:#0071bb></font><b>)</b> </p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:6px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:6px; COLOR:#002c40" align=justify>Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories, for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.</p> <p style="FONT-SIZE:9.5pt; MARGIN-BOTTOM:5px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:5px; COLOR:#002c40" align=justify>The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking, such as statements relating to the efficacy of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s tests, the rapidity of testing results, pricing of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test kits, commencement of FDA clinical trials, completion of clinical trials, favorable outlook pertaining to clinical trial outcomes, the FDA<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s acceptance of clinical trials data, clearance from the FDA for the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s products to be sold in the US, receipt of regulatory approvals for the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s products to be sold outside of the US, demand for domestic US and international orders, availability of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test kits, and patent protection on the test technology. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, including, without limitation: &nbsp;results of studies testing the efficacy of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test; regulatory approvals necessary prior to commercialization of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test and or therapy; availability of the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s test kits; capacity, resource and other constraints on our suppliers; the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s ability to effectively manufacture the test kit once approve for sale; dependence on our third party manufacturers; dependence on international shipping carriers; governmental import/export regulations; demand for our tests or therapy; competition from competitors that have significantly more financial and other resources available to them; governmental virus control regulations that make it difficult or impossible for the company to maintain current operations; regulations and the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s ability to obtain patent protection on any aspects of its test technology. &nbsp;Accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. Additionally, potential risks and uncertainties include, among other things; fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company competes and will be competing, the impact of the coronavirus on the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s operations, revenues and the completion of the clinical trials, the and the Company's dependence on partners and strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.</p> <p style="FONT-SIZE:9.5pt; FONT-FAMILY:Avenir,Times New Roman; COLOR:#002c40; MARGIN:0px; PADDING-RIGHT:15px" align=justify>We are susceptible to a widespread outbreak of an illness or other health issue, such as the recent 2019 CoV-19 Coronavirus (<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>Covid-19 Virus<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>) outbreak first reported in Wuhan, Hubei Province, China in December 2019 and </p> <p style=MARGIN:0px align=justify><br><br></p> <hr size=1 noshade style="MARGIN-BOTTOM:9px; PADDING-TOP:9px"> <p style="FONT-SIZE:9.5pt; FONT-FAMILY:Avenir,Times New Roman; PAGE-BREAK-BEFORE:always; COLOR:#002c40; MARGIN:0px; PADDING-RIGHT:15px" align=justify>subsequently spreading throughout the world resulting in hundreds of thousands of confirmed cases worldwide and many deaths. The outbreak of the Covid-19 Virus has caused the various governments, including the U.S., to implement quarantines, various restrictions on travel causing airlines to suspend international and certain domestic flights, shelter in place orders. Governments have also implemented work restrictions that prohibit many employees from going to work, and for businesses that are allowed to remain open, many employees are electing to remain at home to avoid spread of the disease. As a result of this Covid-19 Virus outbreak and potential future pandemic outbreaks, the Company faces significant risks including, but not limited to; a) supply chain disruptions making it difficult for the Company to order and receive materials needed for production of its products, and needed to ship finished products to our end customers, b) loss of contract and customers from the financial strains or other disruptions they are experiencing as a result of the pandemic, c) financial risks pertaining to receivables due from customers that may fall into insolvency or otherwise be unable to pay their bills, d)government responses including orders that make it difficult to remain open for business, restrict imports of raw materials or exports of finished goods, refuse to allow the Company<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s product to be licensed for sale in their countries, and other seen and unforeseen actions taken by government agencies, e) absenteeism or loss of employees at our Company, or at our partner<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s companies, due to health reasons or government restrictions, that are needed to develop, validate, manufacture and perform other necessary functions for our operations, f) equipment failures, loss of utilities and other disruptions that could impact our operations or render them inoperable, g) litigation or government actions against the Company pertaining to existing products new products sold by the Company that are directed at limiting or treating the spread of the pandemic outbreak, h) a local or global recession or depression that could harm the international banking system, limit demand for all products including those made by the Company, and many other seen and unforeseen events and circumstances, all of which could negatively impact the Company.</p> <p style=MARGIN:6px align=justify><br></p> <p style="FONT-SIZE:11.5pt; MARGIN-BOTTOM:7px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:7px; LINE-HEIGHT:22.5pt"><b>CONTACT INFORMATION</b></p> <p style="FONT-SIZE:10.5pt; MARGIN-BOTTOM:6px; FONT-FAMILY:Avenir,Times New Roman; MARGIN-TOP:6px; COLOR:#002c40; PADDING-LEFT:24px">Company Spokesperson<br>949-645-2111<br><font style=COLOR:#0071bb>www.biomerica.com</font></p><font style=FONT-SIZE:10pt><font style=COLOR:black><font size=+0><font style='FONT-FAMILY:"Calibri",sans-serif; COLOR:black; LINE-HEIGHT:107%'> <p style="VERTICAL-ALIGN:top; BACKGROUND:white; MARGIN:0in 0in 0pt"><font style="FONT-SIZE:9pt; COLOR:#642a8f"><strong><sup>1 </sup></strong>The epidemiology of irritable bowel syndrome. </font><font style=COLOR:black><font style="FONT-SIZE:9pt; COLOR:#642a8f">Clin Epidemiol</font></font><font style="FONT-SIZE:9pt; COLOR:#642a8f">. 2014; 6: 71&#150;80. .&nbsp;doi:&nbsp;&nbsp;</font><font style=COLOR:black><font style="FONT-SIZE:9pt; COLOR:#642a8f">10.2147/CLEP.S40245&nbsp;<font style=COLOR:black><font style="FONT-SIZE:9pt; COLOR:#642a8f">Caroline Canavan</font></font><font style="FONT-SIZE:9pt; COLOR:#642a8f">,&nbsp;</font><font style=COLOR:black><font style="FONT-SIZE:9pt; COLOR:#642a8f">Joe West</font></font><font style="FONT-SIZE:9pt; COLOR:#642a8f">,&nbsp;and&nbsp;</font><font style=COLOR:black><font style="FONT-SIZE:9pt; COLOR:#642a8f">Timothy Card</font></font><font style="FONT-SIZE:9pt; COLOR:#642a8f"></font></p></font></font></font></font></font></font> <p style=MARGIN:6px><br></p> <p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:3pt"><font style=BACKGROUND-COLOR:#ffffff><sup>i</sup></font><font style=BACKGROUND-COLOR:#ffffff> </font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>The epidemiology of irritable bowel syndrome</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>. </u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>Clin Epidemiol</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>. 2014; 6: 71<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#150;</font>80</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>.</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u> </u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>.</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>&nbsp;</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>doi</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>:&nbsp;&nbsp;</u></font><font style="FONT-SIZE:9pt; COLOR:#642a8f; BACKGROUND-COLOR:#ffffff"><u>10.2147/CLEP.S4024</u></font></p></body><!-- EDGAR Validation Code: BB500648 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0^P17AI9@  34T *@    @ ! $2  ,
M   !  $   $Q  (    F    /@$R  (    4    9(=I  0    !    >
M .17:6YD;W=S(%!H;W1O($5D:71O<B Q,"XP+C$P,#$Q+C$V,S@T #(P,C Z
M,#8Z,38@,38Z,34Z-3(   60 P "    %    +J0!  "    %    ,Z2D0 "
M     S0T  "2D@ "     S0T  "@ 0 #     0 !        ,C R,#HP-CHQ
M-B Q-CHQ-#HS,  R,#(P.C V.C$V(#$V.C$T.C,P      8! P #     0 &
M   !&@ %     0   3(!&P %     0   3H!*  #     0 "   " 0 $
M 0   4(" @ $     0  #F8         8     $   !@     ?_8_]L 0P (
M!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W
M*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\
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MN;I?E?RT.$4!@<LP(X)  &3W&F_!#]H34[..XU7XSQZ=>L-S6]K8+(B'KC<
MF?RQ]:YI95*C",\14C#FV3O>WR1U1S>%:<H8:G*=M[6M^+1]4_SHK\^?B5\:
M/CQ^R[XRL+'Q)XCLO%6G72>?;M-;)Y<Z*0'4E55U89'<@9!R:ZO]I?\ :U\2
M6GAOX;S> KV31[_Q#9?VE<0B&.:0*Q58X\.I!^?S!D 9VUM'(\1.5-4Y)QGL
M^GS,'G^&A&HZD7&4-UU/MJBOB[]BC]HSQI\2_B%KOASQGK+:FZV/VFU62WBB
M,;)(JNOR(N2=XR#TVU],_&3XIZ7\&_ &I>)M4.Y;==D%N&P]Q,P^2-?<GOV
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MIFNJ>3RI5_JTJT>?337_ "*I<2UI4/K-.-3D[W_X)]$S?LY_#*;E_ ^AD_\
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MCM*I(_0BBBJ.FC%.=FCYX7]ICQEJ^NC35-A81M_RUMK<EQ_WVS#]*]<T_P
MS^,+6*?6O%WB2\23K!!>)9I],V\<;?F:**74^M=*G3PRG"*3[VU-32_V>OAW
MI=X+M?"UC>7F<_:M14WDV?7?*6;/XUWEK9V]E"L5O!'!&O 6-0 /PHHH/DL1
5B*U:7[R;?JVRT*6BBI.0**** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
